Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
A new study published in The BMJ offers encouraging news for adults with type 2 diabetes and heart conditions. Researchers found that tirzepatide, the main ingredient in Mounjaro, may reduce the risk of major heart problems.
The study suggests that tirzepatide may provide greater cardiovascular benefits than some older diabetes medicines. These findings add to growing evidence about its potential heart health benefits in people with type 2 diabetes.
The research examined health records from about 53,000 adults aged 40 and older. Around 35,000 people were taking tirzepatide. More than 17,000 were taking sitagliptin. Sitagliptin is a common diabetes drug without additional heart-protection benefits.
After one year, the group taking tirzepatide had fewer serious heart issues. About 2.9% of people on tirzepatide suffered a major event, such as a heart attack or stroke, compared to 4.4% of those on sitagliptin. This represents a 32% lower overall risk, mostly due to a clear drop in heart attacks.
The study also uncovered a few extra benefits. Patients on tirzepatide spent less time in the hospital for infections and had lower overall death rates. Because these improvements go beyond basic blood sugar control, scientists plan to research the drug further to figure out how it works inside the body.
However, there are some limits to the findings. Since this was an observational study based on existing medical records rather than a clinical trial, outside factors like diet, exercise, or unrecorded habits could have affected the numbers.
An editorial in the same journal suggested that doctors stay cautiously optimistic. The authors pointed out that while heart attacks decreased, stroke rates remained largely unchanged.
In addition, about 20% of the patients were taking SGLT-2 inhibitors, another type of heart-healthy diabetes medicine. Extra analysis showed tirzepatide offered benefits on its own, but experts need more research to see if it works better than simply fine-tuning current drug regimens.
These results align well with what scientists already know about similar diabetes drugs. Although regulators currently approve tirzepatide for type 2 diabetes and weight loss, doctors now have extra evidence to consider when treating high-risk patients while larger trials continue.
